I think I will lob a letter into my local member too, though there's likely to be a change at the next election! He disgraced himself in the failed Dutton manoeuvre...
@Riki_BCNA Am I correct in the following?
My understanding is that of everyone diagnosed with BC, there is a group that clearly need to have chemotherapy, and a group that clearly don't. However in between there's a group in a grey area. In a large study done recently, they worked out that using oncotype tests only 30% of that group actually need to have chemo.
Has anyone actually done a cost benefit analysis on how that would affect the fiscal bottom line? (Not to mention the suffering...) If the 70% who are currently having chemo 'unnecessarily' didn't have it, would that save the health budget more than the subsidised oncotype tests would cost? And that's even without factoring in the cost of managing the ongoing side effects that many are left with.
I am very interested to know the answer. Thank you.